Here’s what you should know:
1. Analysts believe Allergan will announce fourth quarter 2017 earnings of $0.83 per share Feb. 14, as well.
2. Analysts believe the company’s full-year earnings will increase approximately 13.98 percent, year over year.
3. Based on the projected earnings, 18 analysts awarded Allergan a “buy” rating and eight have deemed it a “hold.” No analysts issued a “sell” rating.
More articles on supply chain:
Healthcare-related lobbying hits $555M in 2017 — 6 statistics on lobbying in healthcare
Advanced Medical Group joins National Spine & Pain Centers — 4 things to know
Preoperative opioid users more likely to abuse opioids after TKA — 3 study insights
